Mavyret ([glecaprevir + pibrentasvir]) is AbbVie’s next-generation, pan-genotypic regimen, which is positioned as a replacement for the Viekira Pak franchise ([paritaprevir + ritonavir + ombitasvir] ± dasabuvir) and is intended to reverse the company’s hepatitis C revenue decline. Mavyret is forecasted to achieve greater commercial success than its predecessor, and will allow AbbVie to quickly recoup the genotype 1/4 (GT-1/4) patient share lost to Zepatier ([grazoprevir + elbasvir]; Merck & Co) during 2016–17 because of its more attractive eight-week dosing schedule in non-cirrhotic patients, as well as AbbVie’s anticipated willingness to discount heavily to achieve uptake.
Mavyret is a once-daily, fixed-dose combination of AbbVie’s second-generation hepatitis C virus NS3/4A protease inhibitor, glecaprevir, and the company’s second-generation NS5A inhibitor, pibrentasvir. The combination is approved in the US, Japan, and EU for the treatment of GT-1/2/3/4/5/6 patients.
TABLE OF CONTENTS
4 PRODUCT PROFILES 4 Mavyret : Hepatitis C
LIST OF FIGURES 12 Figure 1: Mavyret for hepatitis C – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Mavyret for hepatitis C
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Mavyret for hepatitis C
17 Figure 4: Mavyret sales for hepatitis C across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES 5 Table 1: Mavyret drug profile
7 Table 2: Pivotal Phase III studies of Mavyret in hepatitis C
10 Table 3: Other Phase III studies of Mavyret in hepatitis C
11 Table 4: Mavyret ongoing Phase III trials in hepatitis C
18 Table 5: Mavyret sales for hepatitis C across the US, Japan, and five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.